Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Next Previous
Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Allergic asthma; Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms PATHWAY
  • Sponsors Amgen; MedImmune

    • Most Recent Events

    • 07 Nov 2023 Results of pooled analysis from pooled analysis of the PATHWAY and NAVIGATOR , published in the Annals of Internal Medicine
    • 13 Sep 2023 Results of post-hoc pooled analysis from PATHWAY (NCT02054130) and NAVIGATOR(NCT03347279) studies assessing the effect of tezepelumab on pre-BD ppFEV1 in patients grouped by baseline pre-BD ppFEV1 presented at the 33rd Annual Congress of the European Respiratory Society.
    • 24 May 2023 Results assessing efficacy of tezepelumab in patients grouped by baseline ppFEV1 using pooled data from the PATHWAY and NAVIGATOR studies, presented at the 119th International Conference of the American Thoracic Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top